Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma: a propensity score matching analysis of the Brain Tumor Registry of Japan.
Adjuvant radiotherapy
Brain tumor registry
Meningioma
Recurrence
Skull base
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
02
04
2021
accepted:
08
05
2021
pubmed:
19
5
2021
medline:
15
12
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
This study aimed to improve the understanding of the role of adjuvant radiotherapy (AR) after subtotal resection (STR) of World Health Organization (WHO) grade I meningiomas. We retrospectively reviewed the Brain Tumor Registry of Japan database. Among 7341 patients diagnosed with intracranial meningioma during 2001-2008, we identified 406 patients with WHO grade I meningioma treated with STR as initial treatment. Data on progression-free survival (PFS) were assessed for their relevance to clinical factors including age, sex, tumor location and size, presence of preoperative symptoms, and AR. AR was administered for 73 patients (18.0%). Regrowth occurred in 90 cases (22.2%) during the median follow-up period of 6.0 years (interquartile range, 2.7-7.7 years). Multivariate Cox regression analysis of the entire cohort showed that no AR was associated with significantly shorter PFS (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.33-5.42, p = 0.004). The therapeutic effect of AR was confirmed for skull base, but not non-skull base, meningiomas (p = 0.003 and 0.69, respectively). Propensity score matching analysis balanced the influence of confounding factors to generate AR+ and AR- cohorts of 73 patients each. PFS was significantly longer in the AR+ cohort than in the AR- cohort (HR 3.46, 95% CI 1.53-8.59, p = 0.003). Subgroup analysis demonstrated the favorable effect of AR only for skull base meningiomas. Our study revealed that AR improves tumor control after STR in WHO grade I meningiomas. However, this beneficial effect might be limited to skull base meningiomas.
Identifiants
pubmed: 34002302
doi: 10.1007/s11060-021-03775-x
pii: 10.1007/s11060-021-03775-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-360Références
Corell A, Thurin E, Skoglund T, Farahmand D, Henriksson R, Rydenhag B, Gulati S, Bartek J Jr, Jakola AS (2019) Neurosurgical treatment and outcome patterns of meningioma in Sweden: a nationwide registry-based study. Acta Neurochir 161:333–341. https://doi.org/10.1007/s00701-019-03799-3
doi: 10.1007/s00701-019-03799-3
pubmed: 30675656
Lemée JM, Corniola MV, Da Broi M, Schaller K, Meling TR. (2019). Early Postoperative Complications in Meningioma: Predictive Factors and Impact on Outcome. World Neurosurg 128, e851–e858. https://urldefense.proofpoint.com/v2/url?u=http-3A__doi.org_10.1016_j.wneu.2019.05.010&d=DwIFaQ&c=vh6FgFnduejNhPPD0fl_yRaSfZy8CWbWnIf4XJhSqx8&r=r2aSgYn6PHMQXXmeBiKsnvfFG9T9U5fmdQ67xEVmgo0&m=05N_44vN1lB8GHNcXXUlHq5HG5Tn74yZIQSG-WJoX0o&s=llz8KBkUkAmD__eFAjSwArdhDnShpTqycWQpdCSff8&e=
Oya S, Ikawa F, Ichihara N, Wanibuchi M, Akiyama Y, Nakatomi H, Mikuni N, Narita Y (2020) Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: analysis of surgery-related risks. Neurol Med Chir (Tokyo). https://doi.org/10.2176/nmc.oa.2020-0304
doi: 10.2176/nmc.oa.2020-0304
Kolakshyapati M, Ikawa F, Abiko M, Mitsuhara T, Kinoshita Y, Takeda M, Kurisu K, Alumni Association Group of the Department of Neurosurgery at Hiroshima University (2018) Multivariate risk factor analysis and literature review of postoperative deterioration in Karnofsky Performance Scale score in elderly patients with skull base meningioma. Neurosurg Focus 44:E14. https://doi.org/10.3171/2018.1.FOCUS17730
doi: 10.3171/2018.1.FOCUS17730
Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 125:1–10. https://doi.org/10.3171/2015.9.JNS15754
doi: 10.3171/2015.9.JNS15754
Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B (2016) Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. J Neurosurg 126:1–11. https://doi.org/10.3171/2016.1.JNS151842
doi: 10.3171/2016.1.JNS151842
Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, Flickinger JC (2008) Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 62:53–58; discussion 58–60. https://doi.org/10.1227/01.NEU.0000311061.72626.0D
doi: 10.1227/01.NEU.0000311061.72626.0D
pubmed: 18300891
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.JNS131644
doi: 10.3171/2014.7.JNS131644
pubmed: 25343186
pmcid: 5062955
Santacroce A, Walier M, Régis J et al (2012) Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 70:32–39; discussion 39. https://doi.org/10.1227/NEU.0b013e31822d408a
doi: 10.1227/NEU.0b013e31822d408a
pubmed: 21765282
Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39:427–436. https://doi.org/10.1016/s0360-3016(97)00317-9
doi: 10.1016/s0360-3016(97)00317-9
pubmed: 9308947
Soyuer S, Chang EL, Selek U, Shi W, Maor MH, DeMonte F (2004) Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 71:85–90. https://doi.org/10.1016/j.radonc.2004.01.006
doi: 10.1016/j.radonc.2004.01.006
pubmed: 15066300
Taylor BW, Marcus RB, Friedman WA, Ballinger WE Jr, Million RR (1988) The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:299–304. https://doi.org/10.1016/s0360-3016(98)90008-6
doi: 10.1016/s0360-3016(98)90008-6
pubmed: 3403313
Rogers CL, Won M, Vogelbaum MA et al (2020) High-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106:790–799. https://doi.org/10.1016/j.ijrobp.2019.11.028
doi: 10.1016/j.ijrobp.2019.11.028
pubmed: 31786276
Rogers L, Zhang P, Vogelbaum MA et al (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35–47. https://doi.org/10.3171/2016.11.JNS161170
doi: 10.3171/2016.11.JNS161170
pubmed: 28984517
Weber DC, Ares C, Villa S et al (2018) Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042–26042). Radiother Oncol 128:260–265. https://doi.org/10.1016/j.radonc.2018.06.018
doi: 10.1016/j.radonc.2018.06.018
pubmed: 29960684
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131
doi: 10.1093/neuonc/noy131
pubmed: 30445539
pmcid: 6129949
Rogers CL, Perry A, Pugh S et al (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565–574. https://doi.org/10.1093/neuonc/nov247
doi: 10.1093/neuonc/nov247
pubmed: 26493095
Amsbaugh M, Ugiliweneza B, Burton E, Skirboll S, Woo S, Boakye M (2016) Patterns of care and outcomes of adjuvant radiotherapy for meningiomas: a Surveillance, Epidemiology, and End Results and Medicare Linked Analysis. Cureus 8:e567. https://doi.org/10.7759/cureus.567
doi: 10.7759/cureus.567
pubmed: 27186449
Brodbelt AR, Barclay ME, Greenberg D, Williams M, Jenkinson MD, Karabatsou K (2019) The outcome of patients with surgically treated meningioma in England: 1999–2013. A cancer registry data analysis. Br J Neurosurg 33:641–647. https://doi.org/10.1080/02688697.2019.1661965
doi: 10.1080/02688697.2019.1661965
pubmed: 31526136
Cahill KS, Claus EB (2011) Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. J Neurosurg 115:259–267. https://doi.org/10.3171/2011.3.JNS101748
doi: 10.3171/2011.3.JNS101748
pubmed: 21529132
pmcid: 3256743
Reddy AK, Ryoo JS, Denyer S, McGuire LS, Mehta AI (2019) Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis. Neurosurg Focus 46:E3. https://doi.org/10.3171/2019.3.FOCUS1971
doi: 10.3171/2019.3.FOCUS1971
pubmed: 31153148
Maclean J, Fersht N, Short S (2014) Controversies in radiotherapy for meningioma. Clin Oncol (R Coll Radiol) 26:51–64. https://doi.org/10.1016/j.clon.2013.10.001
doi: 10.1016/j.clon.2013.10.001
Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society (2017) Brain Tumor Registry of Japan (2005–2008). Neurol Med Chir (Tokyo) 57:9–102. https://doi.org/10.2176/nmc.sup.2017-0001
doi: 10.2176/nmc.sup.2017-0001
Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society (2014) Brain Tumor Registry of Japan (2001–2004). Neurol Med Chir (Tokyo) 54:1–102
doi: 10.2176/nmc.sup.2014-0000
Ohba S, Kobayashi M, Horiguchi T, Onozuka S, Yoshida K, Ohira T, Kawase T (2011) Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas. J Neurosurg 114:1278–1287. https://doi.org/10.3171/2010.11.JNS10701
doi: 10.3171/2010.11.JNS10701
pubmed: 21166572
Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM (1987) Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 20:525–528. https://doi.org/10.1227/00006123-198704000-00003
doi: 10.1227/00006123-198704000-00003
pubmed: 3587542
Miralbell R, Linggood RM, la Monte de S, Convery K, Munzenrider JE, Mirimanoff RO (1992) The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13:157–164. https://doi.org/10.1007/BF00172765
doi: 10.1007/BF00172765
Goldbrunner R, Minniti G, Preusser M et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383–e391. https://doi.org/10.1016/S1470-2045(16)30321-7
doi: 10.1016/S1470-2045(16)30321-7
National Comprehensive Cancer Network. NCCN: NCCN guidelines: Central Nervous System Cancers. NCCN.org ( http://www.nccn.org/ ). Accessed 31 Mar 2021.
Sun SQ, Hawasli AH, Huang J et al (2015) An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus 38:E3. https://doi.org/10.3171/2015.1.FOCUS14757
doi: 10.3171/2015.1.FOCUS14757
pubmed: 25727225
Hammouche S, Clark S, Wong AHL, Chicoine MR, Kim AH (2014) Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment. Acta Neurochir 156:1475–1481. https://doi.org/10.1007/s00701-014-2156-z
doi: 10.1007/s00701-014-2156-z
pubmed: 24965072
Jenkinson MD, Waqar M, Farah JO et al (2016) Early adjuvant radiotherapy in the treatment of atypical meningioma. J Clin Neurosci 28:87–92. https://doi.org/10.1016/j.jocn.2015.09.021
doi: 10.1016/j.jocn.2015.09.021
pubmed: 26775147
Sun SQ, Kim AH, Cai C et al (2014) Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75:347–354; discussion 354–355; quiz 355. https://doi.org/10.1227/NEU.0000000000000461
doi: 10.1227/NEU.0000000000000461
pubmed: 24932707
Aizer AA, Arvold ND, Catalano P et al (2014) Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncolgoy 16:1547–1553. https://doi.org/10.1093/neuonc/nou098
doi: 10.1093/neuonc/nou098
Bagshaw HP, Burt LM, Jensen RL, Suneja G, Palmer CA, Couldwell WT, Shrieve DC (2017) Adjuvant radiotherapy for atypical meningiomas. J Neurosurg 126:1822–1828. https://doi.org/10.3171/2016.5.JNS152809
doi: 10.3171/2016.5.JNS152809
pubmed: 27611201
Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, FèvreMontange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367–375. https://doi.org/10.1007/s11060-009-9934-0
doi: 10.1007/s11060-009-9934-0
pubmed: 19562258
Hemmati SM, Ghadjar P, Grün A, Badakhshi H, Zschaeck S, Senger C, Acker G, Misch M, Budach V, Kaul D (2019) Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. Radiat Oncol 14:160–167. https://doi.org/10.1186/s13014-019-1368-z
doi: 10.1186/s13014-019-1368-z
pubmed: 31477146
Brown DA, Goyal A, Kerezoudis P et al (2020) Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry. J Neurooncol 149:293–303. https://doi.org/10.1007/s11060-020-03604-7
doi: 10.1007/s11060-020-03604-7
pubmed: 32860156
Wang C, Kaprealian TB, Suh JH, Kubicky CD, Ciporen JN, Chen Y, Jaboin JJ (2017) Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. Neuro Oncol 19:1263–1270. https://doi.org/10.1093/neuonc/nox007
doi: 10.1093/neuonc/nox007
pubmed: 28371851
pmcid: 5570224
Behling F, Fodi C, Hoffmann E et al (2020) The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. Neurosurg Rev 32:1–8. https://doi.org/10.1007/s10143-020-01428-7
doi: 10.1007/s10143-020-01428-7
Magill ST, Dalle Ore CL, Diaz MA, Jalili DD, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Surgical outcomes after reoperation for recurrent non-skull base meningiomas. J Neurosurg 131:1–9. https://doi.org/10.3171/2018.6.JNS18118
doi: 10.3171/2018.6.JNS18118
Magill ST, Lee DS, Yen AJ, Lucas CG, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Surgical outcomes after reoperation for recurrent skull base meningiomas. J Neurosurg 130:876–883. https://doi.org/10.3171/2017.11.JNS172278
doi: 10.3171/2017.11.JNS172278
pubmed: 29726777
Park S, Cha YJ, Suh SH, Lee IJ, Lee KS, Hong CK, Kim JW (2019) Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma. J Cancer Res Clin Oncol 145:1351–1360. https://doi.org/10.1007/s00432-019-02891-6
doi: 10.1007/s00432-019-02891-6
pubmed: 30953136
Tomasello F, Conti A, Cardali S, Angileri FF (2013) Venous preservation–guided resection: a changing paradigm in parasagittal meningioma surgery. J Neurosurg 119:74–81. https://doi.org/10.3171/2012.11.JNS112011
doi: 10.3171/2012.11.JNS112011
pubmed: 23330997
Gomes Dos Santos A, Solla DJF, Moscardi R, Neville IS, Weltman E, Teixeira MJ, Paiva WS (2019) Adjuvant radiotherapy did not reduce recurrence of World Health Organization Grade I meningiomas with venous sinus involvement: a propensity score adjusted analysis and literature review. World Neurosurg 130:e1015–e1019. https://doi.org/10.1016/j.wneu.2019.07.068
doi: 10.1016/j.wneu.2019.07.068
pubmed: 31306847
Lv P, Wang JJ, Xiong NX, Liu XM, Yao DX, Jiang XB, Zhao HY, Zhang FC, Fu P (2021) Long-term outcome in meningiomas involving the major dural sinuses with combined therapy of subtotal resection and early postoperative gamma knife radiosurgery. Acta Neurochir. https://doi.org/10.1007/s00701-021-04766-7
doi: 10.1007/s00701-021-04766-7
pubmed: 33608765
Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289. https://doi.org/10.1038/ng.2526
doi: 10.1038/ng.2526
pubmed: 23334667
pmcid: 3739288
Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
doi: 10.1126/science.1233009
pubmed: 23348505
pmcid: 4808587
Hashimoto N, Rabo CS, Okita Y et al (2012) Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg 116:574–580. https://doi.org/10.3171/2011.11.JNS11999
doi: 10.3171/2011.11.JNS11999
pubmed: 22175721
Yoshimoto K, Kada A, Kuga D et al (2016) Current trends and healthcare resource usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: a National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor). Neurol Med Chir (Tokyo) 56:664–673. https://doi.org/10.2176/nmc.oa.2016-0172
doi: 10.2176/nmc.oa.2016-0172